Upadacitinib is an investigational, oral, small molecule JAK1-selective inhibitor, which recently completed phase 3 clinical trials for treating patients with moderate to severe rheumatoid arthritis (RA). In late 2018, AbbVie Inc. submitted a New Drug Application to the U.S. Food and Drug Administration, as well as a marketing authorization application to the European Medicines Agency,…
U.S. House Democrats Introduce Sweeping Medicare for All Bill
WASHINGTON (Reuters)—Democrats in the U.S. House of Representatives unveiled an ambitious proposal to move all Americans into the government’s Medicare health insurance program, tapping into public frustration over the rising cost of healthcare that has become a key issue for the party as it seeks to gain control of Congress and the White House in…
U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…
Mortality Trends in Lupus Nephritis
According to results of a recent study of all-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014, the all-cause premature mortality rate improved among white, African American and Hispanic patients, with reduced risk of death from CVD and infection. Jorge et al. observed a 32% reduction in mortality. This improved survival may be explained by a combination of improvements in the management of ESRD and of underlying SLE…
AMA RUC Survey of New Evaluation & Management Visit Codes: Your Expertise Required
In the next few weeks, you may be selected to participate in an AMA/Specialty Society RVS Update Committee (RUC) survey for physician office visits (99202-99205, 99211-99215) and a new prolonged services code (99XXX). As you may know, the components of the Medicare Physician Payment Schedule are physician work, practice expense and professional liability insurance. This…
Early Activity Holds Signs of Hope for 2019 State Legislative Cycle
The 2019–2020 legislative cycle in the states holds real hope and opportunity for critical reforms to protect rheumatology practices and patients. It is important to note that because of the state legislative process, bill passage almost always comes later in the legislative session. Although the rheumatology community has not yet seen many official wins, early…
Arthritis Advocacy Spotlights the Military: Veterans, including a rheumatologist, educate lawmakers about arthritis’ impact & the need for research funding
On Feb. 13, the ACR co-sponsored Arthritis 101, its biennial arthritis advocacy lunch briefing at the U.S. Capitol, highlighting the disproportionate impact of rheumatic disease on active members of the armed forces and veterans. The event, co-sponsored by the Arthritis Foundation (AF), is part of the ACR’s effort to support inclusion of $20 million in…
Tanezumab for OA Pain
In a recent study, tanezumab proved more effective than placebo in treating patients with moderate to severe pain caused by hip or knee osteoarthritis…
Extracellular Vesicles May Play an Important Role in Seropositive RA Disease Severity
In a study, researchers found extracellular vesicles may contribute to the greater disease severity typically seen in patients with seropositive rheumatoid arthritis (RA). Specifically, in these patients, extracellular vesicles can activate mononuclear phagocytes and induce proinflammatory cytokines in vitro…
Coverage Requirements for HLA-B27 Vary by Testing Methodology
Did you know a laboratory can perform one of two different tests when a provider orders an HLA-B27 blood test? The ACR Insurance Subcommittee has received several complaints regarding commercial payer coverage for these tests, depending on which methodology the lab employs. To avoid administrative burden, members should familiarize themselves with lab practices and payer…
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 310
- Next Page »